Figure 1. Association between HOTAIRM1 expression and clinical and molecular features and malignancy in glioma. (A) TCGA (top) and CGGA (bottom) data were arranged in ascending order of HOTAIRM1 expression level; the relationship between HOTAIRM1 level and clinical and molecular features of glioma was evaluated. a, Difference in continuous variables between high- and low-exp groups was assessed with the Student’s t test; b, distribution of categorical variables between high- and low-exp groups was assessed with the χ2 test or Fisher’s exact test. (B, C) HOTAIRM1 expression level according to tumor grade, histopathologic classification, and molecular and TCGA subtypes in TCGA (B) and CGGA (C). (D, E) qRT-PCR analysis of relative HOTAIRM1 expression level in four non-neoplastic brain tissue samples, 28 glioma tissue samples (Grade II, n = 10, Grade III, n = 10, and Grade IV, n = 8), normal human astrocytes (NHA), five glioma cell lines, and three primary DGC lines derived from glioma patients. Values represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student’s t test).